SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $2,185,183,006 |
| Positions | 277 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ABIVAX SA | ABVX | SPONSORED ADS | $240,494,722 | 1,804,703 |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $117,782,587 | 960,863 |
| ROIVANT SCIENCES LTD | ROIV | SHS | $111,726,513 | 3,157,008 |
| STATE STR SPDR S&P 500 ETF T | SPY | TR UNIT | $96,398,299 | 129,087 |
| IMMUNOVANT INC | IMVT | COM | $89,802,487 | 2,330,716 |
| ZAI LAB LTD | ZLAB | ADR | $64,011,646 | 3,369,034 |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $47,799,647 | 1,288,053 |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $45,730,234 | 1,222,080 |
| EA SERIES TRUST | BOXX | ALPHA ARCH 1-3 | $39,473,966 | 337,125 |
| CYTOKINETICS INC | CYTK | COM NEW | $39,009,097 | 457,907 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.